Drugs / PALVERAFUSP ALFA
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06764836 | Jul 2024 → Jan 2026 overdue | hepatocellular carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05972460 | Aug 2021 → Dec 2023 | cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07170787 | Oct 2025 → Feb 2029 expected | cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07687914 | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06746870 | Dec 2024 → Nov 2025 overdue | non-small cell lung carcinoma, triple-negative breast carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PALVERAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068162 ↗ |
| Known as | IMM2510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07170787 ↗ |
| Action | Inhibit | “IMM2510(Anti-PD-L1 and VEGF trap recombinant protein)” NCT07170787 ↗ |
| Modality | Protein / enzyme biologic | “IMM2510, a PD-L1 and VEGF bispecific fusion protein” NCT05972460 ↗ |
| Route | Intravenous | “IMM2510 is administered via intravenous infusion every 2 weeks up to 52 weeks.” NCT05972460 ↗ |